Cargando…

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation

BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldassari, Laura E, Planchon, Sarah M, Bermel, Robert A, Nakamura, Kunio, Fisher, Elizabeth, Feng, Jenny, Sakaie, Ken E, Ontaneda, Daniel, Cohen, Jeffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831979/
https://www.ncbi.nlm.nih.gov/pubmed/31723439
http://dx.doi.org/10.1177/2055217319887198
_version_ 1783466090275274752
author Baldassari, Laura E
Planchon, Sarah M
Bermel, Robert A
Nakamura, Kunio
Fisher, Elizabeth
Feng, Jenny
Sakaie, Ken E
Ontaneda, Daniel
Cohen, Jeffrey A
author_facet Baldassari, Laura E
Planchon, Sarah M
Bermel, Robert A
Nakamura, Kunio
Fisher, Elizabeth
Feng, Jenny
Sakaie, Ken E
Ontaneda, Daniel
Cohen, Jeffrey A
author_sort Baldassari, Laura E
collection PubMed
description BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. METHODS: Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. RESULTS: There were significant (p<0.01) correlations between serum neurofilament light chain concentration and gadolinium-enhancing lesion number (rho = 0.55) and volume (rho = 0.65), and new/enlarging T2 lesions (rho = 0.65). Patients without disease activity had lower fluctuation in serum neurofilament light chain concentration (p = 0.01). Mean pre- versus post-treatment serum neurofilament light chain concentration values were not significantly different. CONCLUSIONS: Serum neurofilament light chain concentration correlated with magnetic resonance imaging measures of disease activity cross sectionally and longitudinally, and was stable in patients without disease activity. There was no clear treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration.
format Online
Article
Text
id pubmed-6831979
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-68319792019-11-13 Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation Baldassari, Laura E Planchon, Sarah M Bermel, Robert A Nakamura, Kunio Fisher, Elizabeth Feng, Jenny Sakaie, Ken E Ontaneda, Daniel Cohen, Jeffrey A Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. METHODS: Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. RESULTS: There were significant (p<0.01) correlations between serum neurofilament light chain concentration and gadolinium-enhancing lesion number (rho = 0.55) and volume (rho = 0.65), and new/enlarging T2 lesions (rho = 0.65). Patients without disease activity had lower fluctuation in serum neurofilament light chain concentration (p = 0.01). Mean pre- versus post-treatment serum neurofilament light chain concentration values were not significantly different. CONCLUSIONS: Serum neurofilament light chain concentration correlated with magnetic resonance imaging measures of disease activity cross sectionally and longitudinally, and was stable in patients without disease activity. There was no clear treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. SAGE Publications 2019-11-05 /pmc/articles/PMC6831979/ /pubmed/31723439 http://dx.doi.org/10.1177/2055217319887198 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Baldassari, Laura E
Planchon, Sarah M
Bermel, Robert A
Nakamura, Kunio
Fisher, Elizabeth
Feng, Jenny
Sakaie, Ken E
Ontaneda, Daniel
Cohen, Jeffrey A
Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title_full Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title_fullStr Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title_full_unstemmed Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title_short Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
title_sort serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831979/
https://www.ncbi.nlm.nih.gov/pubmed/31723439
http://dx.doi.org/10.1177/2055217319887198
work_keys_str_mv AT baldassarilaurae serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT planchonsarahm serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT bermelroberta serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT nakamurakunio serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT fisherelizabeth serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT fengjenny serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT sakaiekene serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT ontanedadaniel serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation
AT cohenjeffreya serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation